255 related articles for article (PubMed ID: 31106664)
1. Perception of hematologists and oncologists about the biosimilars: A prospective Tunisian study based on a survey.
Hadoussa S; Bouhlel M; Soussi MA; Drira C; Hadoussa M; Khrouf MR
J Oncol Pharm Pract; 2020 Jan; 26(1):124-132. PubMed ID: 31106664
[TBL] [Abstract][Full Text] [Related]
2. [Knowledge and perceptions of biosimilar medicines by health professionals in Tunisia].
Mhiri A; Khemakhem M; Kalboussi N; Kacem B
Ann Pharm Fr; 2022 May; 80(3):327-339. PubMed ID: 34428456
[TBL] [Abstract][Full Text] [Related]
3. Medical Oncologists' Knowledge and Perspectives on the Use of Biosimilars in the United States.
Peipert JD; Kaiser K; Kircher S; Greene GJ; Shaunfield S; Hauner K; Cella D; Mroczek DK
JCO Oncol Pract; 2023 Mar; 19(3):e457-e464. PubMed ID: 36623249
[TBL] [Abstract][Full Text] [Related]
4. Biosimilar Knowledge Among Oncology/Hematology Team Members in Colorado, USA: An Educational Initiative and Follow-Up Survey.
Ismailov RM; Khasanova ZD
BioDrugs; 2018 Oct; 32(5):499-506. PubMed ID: 30120705
[TBL] [Abstract][Full Text] [Related]
5. A consensus statement on the use of biosimilar medicines in hematology in Australia.
Gregory GP; Carrington C; Cheah CY; Hawkes EA; Irving IM; Siderov J; Opat S
Asia Pac J Clin Oncol; 2020 Aug; 16(4):211-221. PubMed ID: 32285612
[TBL] [Abstract][Full Text] [Related]
6. Perception of pharmacological equivalence of generics or biosimilars in healthcare professionals in Vienna.
Binder L; Zeitlinger M
Eur J Clin Pharmacol; 2024 Mar; 80(3):355-366. PubMed ID: 38133831
[TBL] [Abstract][Full Text] [Related]
7. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians.
Cohen H; Beydoun D; Chien D; Lessor T; McCabe D; Muenzberg M; Popovian R; Uy J
Adv Ther; 2017 Jan; 33(12):2160-2172. PubMed ID: 27798772
[TBL] [Abstract][Full Text] [Related]
8. Unveiling the Biosimilar Paradox of Oncologists' Perceptions and Hesitations in South Korea: A Web-Based Survey Study.
Shin G; Kim BS; Kim DY; Bae S
BioDrugs; 2024 Mar; 38(2):301-311. PubMed ID: 38212516
[TBL] [Abstract][Full Text] [Related]
9. Biosimilar Use in Breast Cancer Treatment: A National Survey of Brazilian Oncologists' Opinions, Practices, and Concerns.
Resende HM; Ladislau L; Cardoso ACF; Brandão JDP; Assis BR; Cardoso P; Marassi PHA; Castilho V
JCO Glob Oncol; 2021 Aug; 7():1316-1324. PubMed ID: 34415791
[TBL] [Abstract][Full Text] [Related]
10. Current status of biosimilars in Turkey: A survey among medical oncologists.
Gürler F; Kasım DD; Kurt İnci B; Sütçüoğlu O; Ünsal O; Aslan V; Tahtacı G; Özdemir N; Üner A; Günel N; Özet A; Yazıcı O
J Oncol Pharm Pract; 2022 Oct; 28(7):1516-1523. PubMed ID: 34313505
[TBL] [Abstract][Full Text] [Related]
11. Physicians prefer greater detail in the biosimilar label (SmPC) - Results of a survey across seven European countries.
Hallersten A; Fürst W; Mezzasalma R
Regul Toxicol Pharmacol; 2016 Jun; 77():275-81. PubMed ID: 27041395
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Physicians' Knowledge and Attitudes Towards Biosimilars in Russia and Issues Associated with Their Prescribing.
Karateev D; Belokoneva N
Biomolecules; 2019 Feb; 9(2):. PubMed ID: 30754705
[TBL] [Abstract][Full Text] [Related]
13. Assessing biosimilar education needs among oncology pharmacy practitioners worldwide: An ISOPP membership survey.
Chan A; Patel H; Siderov J; Bubalo J; Foreman E
J Oncol Pharm Pract; 2020 Apr; 26(3_suppl):11-21. PubMed ID: 32268832
[TBL] [Abstract][Full Text] [Related]
14. Medical specialists' attitudes to prescribing biosimilars.
Hemmington A; Dalbeth N; Jarrett P; Fraser AG; Broom R; Browett P; Petrie KJ
Pharmacoepidemiol Drug Saf; 2017 May; 26(5):570-577. PubMed ID: 28233367
[TBL] [Abstract][Full Text] [Related]
15. Current Japanese Regulatory Systems for Generics and Biosimilars.
Kuribayashi R; Sawanobori K
J Pharm Sci; 2018 Mar; 107(3):785-787. PubMed ID: 29113922
[TBL] [Abstract][Full Text] [Related]
16. [Knowledge about Biosimilars in Primary Care: a study by the Spanish Society of Primary Care Physicians (SEMERGEN)].
Micó-Pérez RM; Payares-Herrera C; Palomo-Jiménez PI; Sánchez-Fierro J; Avendaño-Solá C; Llisterri-Caro JL
Semergen; 2018 Sep; 44(6):380-388. PubMed ID: 29459003
[TBL] [Abstract][Full Text] [Related]
17. A survey of global biosimilar implementation practice conducted by the International Society of Oncology Pharmacy Practitioners.
Foreman E; Patel H; Siderov J; Harchowal J; Bubalo J; Chan A
J Oncol Pharm Pract; 2020 Apr; 26(3_suppl):22-32. PubMed ID: 32268828
[TBL] [Abstract][Full Text] [Related]
18. Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and Trust.
Cazap E; Jacobs I; McBride A; Popovian R; Sikora K
Oncologist; 2018 Oct; 23(10):1188-1198. PubMed ID: 29769386
[TBL] [Abstract][Full Text] [Related]
19. A survey of pharmacists' knowledge and views of biosimilars in Quebec and France.
Adé A; Bourdon O; Bussières JF
Ann Pharm Fr; 2017 Jul; 75(4):267-275. PubMed ID: 28237527
[TBL] [Abstract][Full Text] [Related]
20. A Survey Assessment of US Dermatologists' Perception of Biosimilars.
Barsell A; Rengifo-Pardo M; Ehrlich A
J Drugs Dermatol; 2017 Jun; 16(6):612-615. PubMed ID: 28686780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
